Boston Scientific Recalls Balloon Devices
Posted on: Thursday, 8 December 2005, 12:00 CST
NATICK, Mass. - Medical device maker Boston Scientific Corp. said Thursday it is recalling 40,000 implantable devices meant to treat blocked coronary arteries, saying it has received eight complaints that the end of the device became detached as it was inserted in the patient and required more surgery in three cases.
The recall affects all of its Flextome cutting angioplasty balloon devices that the Food and Drug Administration approved as recently as September.
The device differs from standard angioplasty balloons in that it is lined on the outside with three or four lengthwise microsurgical blades. During angioplasty, a balloon catheter is snaked into a congested artery and inflated to reopen the blood vessel and push back accumulated plaque.
Boston Scientific said it received eight complaints that the device tip separated from the catheter as it was removed from the patient, and said surgery was needed in three cases to remove the tip.
The company said it is working with the FDA on the recall and notifying officials from other countries. The Flextome was approved in Europe in January. Boston Scientific booked $13 million in Flextome sales in 2005.
This is the second recall of a balloon-related device in as many years for Boston Scientific. The company recalled thousands of its Taxus Express2 drug-coated stents last summer after reports that the balloon used to place the stent did not deflate in some instances causing injury to the patient.
The recall marks Boston Scientific's second within a week. On Friday, the company announced the recall of about 18,000 devices that filter and dissolve blood clots from entering the lungs. The recall was triggered by eight complaints that the capsule carrying the filter during implantation became detached from the delivery system, causing one patient death.
The announcement comes after Boston Scientific made a $25 billion offer Monday for rival medical device maker Guidant Corp., potentially derailing Guidant's plans to be acquired at a lower price by Johnson & Johnson.
Boston Scientific shares rose 2 cents to $25.83 in morning trading on the New York Stock Exchange.
Source: Associated Press/AP Online
Related Articles
- American Heart Association Late-Breaking Clinical Trial Report: One-Year Mortality Similar In Patients Undergoing Angioplasty for Acute Heart Attacks at Hospitals With and Without Cardiac Surgery Capability
- Boston Scientific's Most Advanced Devices to Treat Heart Failure and Sudden Cardiac Death Now Available in Japan
- Recall Solutions Helping Dentists Thrive in Tough Economy Through Personalized Dental Recall System - Patients Happy
- Study Results Show That Minimally Invasive Therapy is Successful for Over Two-Thirds of Stroke Patients Treated Outside the Standard Eight-Hour Window
- Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
- Nephros, Inc. Receives the 2009 Frost & Sullivan Medical Device Patient Care Company of the Year Award
- Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) and Boston Scientific's Taxus(R) Stent in Patients at High Risk of Restenosis
- Boston Mystery Devices a Cartoon Marketing Ploy
- Boston Scientific Announces Recall
- Patient Fears As NHS Complaints Body Axed
 |
 |
User Comments (0)
RSS Feeds